---
schema_version: "secwatch.filing_event.v1"
accession: "0000879169-23-000014"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2023-05-02T23:59:59+00:00"
generated_at: "2026-06-16T04:21:52.059214+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Incyte Q1: Jakafi rev $580M (+7%); Opzelura $57M (+343%); raises Jakafi FY guidance to $2.55-2.63B

## Summary
- Total net product revenues $693M (+14% YoY); total GAAP revenues $808.7M (+10% YoY).
- GAAP net income $21.7M ($0.10 diluted EPS) vs $38.0M ($0.17) in Q1 2022; Non-GAAP net income $84.6M ($0.37).
- Jakafi FY 2023 guidance raised: bottom end to $2.55B from $2.53B; new range $2.55-$2.63B.
- FDA issued complete response letter for ruxolitinib XR (once-daily) in MF, PV, GVHD; next steps unclear.
- Discontinued parsaclisib combo trials in MF (LIMBER-304/313) and development in wAIHA; axatilimab Phase 2 cGVHD data on track for mid-2023.

## SEC filing metadata
- accession: 0000879169-23-000014
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2023-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000087916923000014/0000879169-23-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000087916923000014/incy-20230502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879169-23-000014
- JSON: https://secwatch.observer/filing/0000879169-23-000014.json
- Plain text: https://secwatch.observer/filing/0000879169-23-000014.txt

## Key facts
- Earnings Releases
  INCYTE CORP reported first fiscal quarter ended March 31, 2023 results: revenue $693 million. Guidance raised.
  - Period: first fiscal quarter ended March 31, 2023
  - Revenue: $693 million
  - Guidance: raised
  - Result: reported results
  source text: FOR IMMEDIATE RELEASE Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs – Total net product revenues of $693 million in Q1'23 (+14% Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $580 million (+7% Y/Y) in Q1'23; raising the bottom end of full year guidance to new range of $2.55 - $2.63 billion for FY 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/879169/000087916923000014/0000879169-23-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.